Search Results 11-20 of 17202 for GLP-1 injections

  1. Mayo Clinic Minute: Weaning off popular weight-loss medications

    You step on the scale and the numbers are moving in the right direction after taking one of the popular injectable weight-loss drugs. But now you want to ...

  2. Contribution of GLP-1 Receptor - Mayo Clinic

    The GLP-1 receptor gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the ...

  3. Lixisenatide (subcutaneous route) - Side effects & dosage - Mayo Clinic

    This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist. ... Your doctor will teach you how the injections are to be given. ... It is not safe for one ...

  4. Genetic test predicts response to weight-loss drugs - Mayo Clinic News Network

    ... GLP-1 drug, liraglutide (Saxenda). They found that: People with a high satiation threshold lost more weight on phentermine-topiramate. This drug may help ...

  5. Glucagon (injection route) - Side effects & dosage - Mayo Clinic

    If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Aclidinium; Amantadine ...

  6. Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes - Mayo Clinic

    GLP-1 is a hormone made by the body that promotes the production of insulin in response to eating. However, there is increasing evidence that this hormone might ...

  7. Mayo Clinic Minute: Using combined therapy to treat obesity

    Using combined therapy to treat obesity, combining bariatric surgery, also called metabolic surgery, with GLP-1 medications. Learn more.

  8. Preoperative Gastric Content With Ultrasound Assessment in Patients Taking GLP1 Agonists - Mayo Clinic

    ... glucagon-like peptide 1 (GLP-1) agonist medications compared to patients who do not take GLP-1 agonists. Participation eligibility. Participant eligibility ...

  9. Evaluation of the changes in glycemic and physiologic parameters (sleep, cardioadapatbility parameters) in non-diabetic patients being treated for obesity with GLP1 Agonist and GLP-1/ GIP agonist medications. - Mayo Clinic

    ... GLP1 Agonist and GLP-1/ GIP agonist medications. Print details. Share ... It is proposed that participants will wear the devices for a period of 28 days before ...

  10. Obesity - Diagnosis and treatment - Mayo Clinic

    Also approved by the FDA is a class of drugs known as glucagonlike peptide 1 agonists, also called GLP-1 agonists. Some of these medicines are approved ...